MAAT INDEX

CLAIM #56405 · Thermo Fisher Scientific Inc (TMO) · 2024Q1 earnings call · Apr 24, 2024 · due Jun 30, 2024

In Q2, we expect revenue dollars to step up from the first quarter, and organic growth will likely be 2 points better than Q1.

Stephen Williamson · CFO

CANNOT_DETERMINE
versus commitment · official band 5 percent
Committed
organic growth will likely be 2 points better than Q1
Reported
core organic revenue growth rounded up to flat on a year-over-year basis

How to check this claim

Look at: Organic revenue growth rate, Q2 2024 vs Q1 2024 organic revenue growth rate

It came true if: Q2 2024 organic growth rate >= Q1 2024 organic growth rate + 2 percentage points (also revenue dollars in Q2 higher than Q1)

Where: Company quarterly earnings release / income statement (Q1 and Q2 2024 10-Q and press release organic growth disclosures)

In context

that the $0.07 beat that we saw in Q1 is offset in the remainder of the year, leading to no change for the year as a whole for FX versus our prior guide. We expect the adjusted income tax rate will be 10.5% in 2024. And we're assuming between $1.3 billion and $1.5 billion of net capital expenditures and free cash flow in the range of $6.5 billion to $7 billion. In terms of capital deployment. We're assuming $3 billion of share buybacks, which were completed in January. We expect to return approximately $600 million of capital to shareholders this year through dividends, we continue to see [ we will close ] the Olink acquisition by midyear. Full year average diluted share count is assumed to be approximately 383 million shares. And finally, I wanted to touch on quarterly phasing. In Q2, we expect revenue dollars to step up from the first quarter, and organic growth will likely be 2 points better than Q1. And we expect Q2 adjusted EPS to be similar to Q1. This reflects the revised view of the phasing of spending within the year that I mentioned. I think this view of Q2 is pretty close to what's currently baked into consensus right now. So to conclude. We delivered on our commitments in Q1, and we're in a great position to deliver differentiated performance for all our stakeholders in 2024. With that, I'll turn the call back over to Raf. Rafael Tejada: Operator, we're ready for the Q&A portion of the call. Operator: [Operator Instructions] We have the first question from Doug Schenkel with Wolfe Research. Douglas Schenkel: Simply put, it was a better start than expected to the year. Marc, can you share color on: one, how did the quarter progress; and two, how does that progression.

Verify independently

SEC filings for TMO · Claim quote is verbatim from the 2024Q1 earnings call.